COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
University of Cambridge > Talks.cam > Cambridge Neuroscience Interdisciplinary Seminars > Can we have jam today and jam tomorrow? Improving outcomes for older people living with mental illness using applied and translational research
Can we have jam today and jam tomorrow? Improving outcomes for older people living with mental illness using applied and translational researchAdd to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact Dr Dervila Glynn. Theme: Lifelong Brain Development and Brain Ageing This talk will examine how approaches such as ‘big data’ and new ways of delivering clinical trials can improve current services for older people with mental illness (jam today) and identify and deliver new treatments in the future (jam tomorrow). Dr Ben Underwood Director of Research & Development CPFT Rasha De Marco Associate Director of Research & Development CPFT Ben studied natural science at Oxford University and medicine at St Bartholomew’s Hospital in London. He completed his psychiatric training in Cambridge where he also undertook a PhD in molecular neurogenetics with Professor David Rubinsztein, looking at autophagy as a therapeutic strategy in neurodegeneration. He is assistant professor in applied and translational old age psychiatry at the University of Cambridge, an honorary consultant old age psychiatrist and R and D director at CPFT . His interests are in translational medicine in dementia where he has been PI for academic and pharma led clinical trials of novel CTIM Ps. He is clinical director of the Windsor research unit, a facility dedicated to joining NHS patients with clinical research. He is the NIHR CRN dementia lead for the east of England and national dementia lead for stratified medicine. During the coronavirus pandemic his working life took an unexpected turn when he became a co-investigator on a number of coronavirus studies, including the Oxford/Astra Zenica vaccine study. Along with Mark Toshner he delivers the Cambridge Advance online course in novel clinical trial design in translational medicine at the University of Cambridge. Register in advance for this meeting: https://us02web.zoom.us/meeting/register/tZctduqvpz8tHNRK4gtJBU-AQduXvjibUxMg After registering, you will receive a confirmation email containing information about joining the meeting. This talk is part of the Cambridge Neuroscience Interdisciplinary Seminars series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listsNew Era in Russian Politics: Mayoral Campaign of Alexey Navalny srgOther talksBreaking the red limit: photosynthesis in far-red light Immunosuppression for Parkinson's disease - a new therapeutic strategy? Gateway- CCIMI Learning About Long COVID from Patients: The Power of Narrative Evidence Insects in Flight |